Bench-to-bedside review: Current evidence for extracorporeal albumin dialysis systems in liver failure

Table 2 Molecular Adsorbent Recirculation System in acute liver failure

				Improvements
Study	Etiology	Number	Controlled	Biochemical	CVS	CNS	Survival (30 days)
Novelli et al. [39]	Fulminant	9	No	Yes	N/A	Yes^a	66%
Isoniemi et al. [40]	Toxic	26	No	Yes	N/A	N/A	88%
Tsai et al. [19]	Hepatitis B virus	10	No	Yes	Yes	Yes	30%
Lee et al. [20]	Drug (herb)	13	No	Yes	N/A	No	15%
Lai et al. [21]	Drug/Non-A non-B hepatitis	10	No	No	Yes^b	No	30%
Camus et al. [41]	Mixed	23	No	Yes^c	N/A	Yes	N/A
Schmidt et al. [17]	Hepatitis B virus/Acetominophen	13	Yes	Yes^c	Yes	N/A	No (62.5% versus 60%)
El Banayosi et al. [18]	Ischemia	27	Yes	No^d	N/A	N/A	Yes (50% versus 32%)

Biochemical improvements: statistically significant reduction in bilirubin, bile acids, creatinine, and ammonia. ^aStatistics not provided; ^bstatistically significant after first but not second MARS treatment; ^conly bilirubin and creatinine were statistically significant; ^dnon-significant improvement in bilirubin. CNS, improvement in hemodynamic parameters (mean arterial pressure, heart rate, vasopressor requirements); CNS, decrease in hepatic encephalopathy grade (neurological improvement); N/A, not assessed.

ISSN: 1364-8535